Kane Biotech Restarts Commercial Activities and Strengthens North American Management

Executive Summary

• Kane Biotech announces the resumption of commercial sales of its revyve® Antimicrobial Wound Gel and Spray in both the United States and Canada.
• The company has executed non‑exclusive distribution agreements with Medstream Healthcare Solutions (FL) and Patient Care Medical (TX) in the U.S., and converted its Canadian agreement with Best Buy Medical Canada to a non‑exclusive arrangement.
• Two Vice Presidents of Business Development were appointed – Kay Watkins Weaver for the United States and Patti Burke‑Martin for Canada – to drive market penetration and growth.

Key Details

• Regulatory Status: revyve® Antimicrobial Wound Gel and Spray are FDA 510(k) cleared; the gel is also Health Canada approved.
• U.S. Distribution Agreements:
• Medstream Healthcare Solutions, LLC (Dorval, FL) – non‑exclusive sales/distribution agreement.
• Patient Care Medical (Austin, TX) – non‑exclusive sales/distribution agreement.
• Initial shipments are expected in the near term.
• Canadian Distribution Arrangement:
• Existing agreement with Best Buy Medical Canada converted to a non‑exclusive model.
• Targeted sales and sampling initiatives underway.
• Commercial Impact: Sales to date in both markets are not material, but represent a meaningful restart of Kane’s commercial engine.
• Management Appointments:
• Sherida (Kay) Watkins Weaver – Vice President, Business Development, United States; >20 years wound‑care commercialization experience (Omeza, Relevate Health).
• Patti Burke‑Martin – Vice President, Business Development, Canada; senior roles at EO2 Concepts, Coloplast, ConvaTec.
• Leadership Quote: “We are executing on our commitment to reset Kane Biotech using a disciplined market approach,” said Dr. Robert Huizinga, Interim CEO.
• Future Outlook: The company will continue building scientific credibility, clinical validation, and expanding its commercial infrastructure across North America.